Scholarlink

Background <p>Circulating tumor DNA (ctDNA) is a promising biomarker for monitoring minimal residual disease (MRD), assessing disease status, and guiding treatment in diffuse large B-cell lymphoma (DLBCL). Current ctDNA assays rarely detect immunoglobulin (IG) fusions. This study evaluates a novel assay that simultaneously detects mutations, IG fusions, and IG V(D)J clonality in plasma and cerebrospinal fluid (CSF) to enhance molecular profiling and CNS monitoring.</p> Methods <p>A prospective analysis was conducted in 57 DLBCL patients. Genomic alterations in plasma and CSF ctDNA were compared to those in tumor tissue using targeted next-generation sequencing (NGS).</p> Results <p>Mutations, IG fusions, and IG V(D)J clonality were detected in 100%, 72.2%, and 78.6% of plasma ctDNA samples, respectively. Plasma ctDNA also revealed additional mutations absent in tumor tissue, reflecting clonal heterogeneity. The incorporation of IG fusion detection enabled molecular subtyping without requiring FISH. In CSF, ctDNA analysis identified genomic alterations in 8 cases, whereas conventional imaging and cytology confirmed CNS involvement in only 3, demonstrating the superior sensitivity of ctDNA for CNS surveillance.</p> Conclusion <p>This ctDNA assay offers a non-invasive, integrated approach for genomic profiling and disease monitoring in DLBCL, with improved sensitivity for CNS detection and potential to inform personalized treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating tumor DNA from blood and cerebrospinal fluid in DLBCL: simultaneous evaluation of mutations, IG rearrangement, and IG clonality

  • 期刊论文

  • 发表日期：

    2025年10月9日

查看全文
  • Han Zhang,
  • Lingfeng Liu,
  • Xiaohui Zhang,
  • Ping Chen,
  • Xingping Lang,
  • Jingjing Feng,
  • Yiting Wang,
  • Yufei Xie,
  • Shouli Wang,
  • Sheng Xiao,
  • Bingzong Li

摘要

Background

Circulating tumor DNA (ctDNA) is a promising biomarker for monitoring minimal residual disease (MRD), assessing disease status, and guiding treatment in diffuse large B-cell lymphoma (DLBCL). Current ctDNA assays rarely detect immunoglobulin (IG) fusions. This study evaluates a novel assay that simultaneously detects mutations, IG fusions, and IG V(D)J clonality in plasma and cerebrospinal fluid (CSF) to enhance molecular profiling and CNS monitoring.

Methods

A prospective analysis was conducted in 57 DLBCL patients. Genomic alterations in plasma and CSF ctDNA were compared to those in tumor tissue using targeted next-generation sequencing (NGS).

Results

Mutations, IG fusions, and IG V(D)J clonality were detected in 100%, 72.2%, and 78.6% of plasma ctDNA samples, respectively. Plasma ctDNA also revealed additional mutations absent in tumor tissue, reflecting clonal heterogeneity. The incorporation of IG fusion detection enabled molecular subtyping without requiring FISH. In CSF, ctDNA analysis identified genomic alterations in 8 cases, whereas conventional imaging and cytology confirmed CNS involvement in only 3, demonstrating the superior sensitivity of ctDNA for CNS surveillance.

Conclusion

This ctDNA assay offers a non-invasive, integrated approach for genomic profiling and disease monitoring in DLBCL, with improved sensitivity for CNS detection and potential to inform personalized treatment strategies.